PSH.F - Sernova Corp.

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Sernova Corp.

The Stiller Centre
Suite 114 700 Collip Circle
London, ON N6G 4X8

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Philip M. Toleikis B.A., M.Sc., Ph.D.Pres, CEO & Director534kN/AN/A
Mr. David Swetlow C.A, C.A., CPAChief Financial Officer290.92kN/AN/A
Mr. Christopher BarnesVP of Investor Relations121.31kN/AN/A
Dr. Frank Shannon M.D.VP of Clinical Devel. & Regulatory Affairs238.67kN/AN/A
Mr. Douglas MaretChief Science OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells;a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform; and research collaboration with AstraZeneca PLC to evaluate novel potential therapeutic cell applications. The company was incorporated in 1998 and is headquartered in London, Canada.

Corporate Governance

Sernova Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.